Company profile: Quiver Bioscience
1.1 - Company Overview
Company description
- Provider of human disease models using stem cell and CRISPR engineering for high-throughput screening; proprietary optogenetic electrophysiology and software to measure neuronal activity; AI/ML analytics to decode CNS biology and identify disease phenotypes and candidates; and drug discovery combining single-cell imaging, multi-omics and proprietary engineering to create transformational medicines.
Products and services
- Disruptive Drug Discovery: Q-State Biosciences architects transformational CNS medicines by integrating advanced single-cell imaging and multi-omics with proprietary engineering and AI/ML in a custom-engineered discovery platform
- Models: Q-State Biosciences engineers human cellular models relevant to disease using stem cell technologies and CRISPR engineering for high-throughput drug screening
- Insights: Q-State Biosciences deploys AI-driven computational analytics to analyze complex CNS biology, identifying disease phenotypes and therapeutic candidates
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Quiver Bioscience
NeuroNexus
HQ: United States
Website
- Description: Provider of neural interface technology, components, and systems for neuroscience and clinical applications, including high-density SiNAPS CMOS probes; X-Series modular connector packages; X-Headstage implantable devices for recording and stimulation; XDAQ Core and XDAQ One electrophysiology data acquisition systems with IO Expander; and Z-Coat site coating to enhance probe performance in brain tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroNexus company profile →
Allon Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical drug development for neurodegenerative diseases, with lead product Davunetide intranasal in Phase IIa clinical trials for Alzheimer's disease, schizophrenia cognitive impairment, and frontotemporal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allon Therapeutics company profile →
Adelia Therapeutics
HQ: United States
Website
- Description: Provider of a drug discovery platform developing proprietary tryptamine-based therapeutics to treat central nervous system (CNS) disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adelia Therapeutics company profile →
Vanda Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on central nervous system disorders, developing and commercializing innovative products through clinical and commercial stage programs, including HETLIOZAccess: an expanded access program for Non-24-Hour Sleep-Wake Disorder (Non-24).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanda Pharmaceuticals company profile →
Vapogenix
HQ: United States
Website
- Description: Provider of clinical-stage non-narcotic topical analgesics for localized pain, including VPX638, a Phase 2 topical for wound pain demonstrating rapid and prolonged relief without systemic side effects; a rapid-acting topical for acute procedural pain on intact skin; and a topical for localized inflammatory pain combining analgesic and anti-inflammatory effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vapogenix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Quiver Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Quiver Bioscience
2.2 - Growth funds investing in similar companies to Quiver Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Quiver Bioscience
4.2 - Public trading comparable groups for Quiver Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →